Paige’s AppLab expansion, adding six leading digital pathology and AI providers. This enhancement empowers pathologists globally, offering seamless access to advanced diagnostic tools and fostering collaboration. Through meticulous integration and commitment to real-world clinical utility, Paige reaffirms its position as a frontrunner in digital pathology solutions, driving innovation and improving patient outcomes.
Paige, a renowned global leader in providing end-to-end digital pathology solutions and clinical Artificial Intelligence (AI) applications for cancer diagnosis, has recently announced a substantial expansion of its AppLab marketplace. This expansion entails the inclusion of six distinguished digital pathology and AI providers, reinforcing Paige’s commitment to delivering a comprehensive and streamlined user experience for diagnosing cancer.
Paige’s Cutting-Edge AppLab Expansion
The addition of new applications from prominent companies such as Imagene, Histofy, Aiosyn, Clinsight, DoMore Diagnostics, and Stratipath* marks a significant enhancement to the Paige AppLab ecosystem. These cutting-edge applications are tailored to support pathology labs worldwide by offering deeply integrated and customizable AI-enabled workflows, thereby facilitating more efficient and accurate cancer diagnosis processes.
The Paige AppLab serves as a dynamic marketplace where pathologists can effortlessly explore, evaluate, and acquire a diverse array of diagnostic support tools from various providers with just a few clicks. This seamless integration enables pathologists to access these tools within the Paige Platform and FullFocus viewer, empowering them to address the unique challenges encountered at each stage of cancer diagnosis. Moreover, the AppLab prioritizes vendor-neutrality and flexibility, ensuring that labs have access to a comprehensive suite of insights from Paige and its partners to effectively meet the evolving needs of patients.
The newly introduced applications introduce advanced AI-powered functionalities, including biomarker detection from H&E-stained slides, assistance in grading and assessing cancer across different tissue types, and risk stratification, among others. Paige has collaborated closely with each AppLab vendor to seamlessly integrate their technologies into the Paige Platform, streamlining the adoption of AI and advancing the field of digital pathology.
Commenting on the partnership, Dr. Torbjørn Furuseth, Co-Founder and CEO of DoMore Diagnostics, expressed enthusiasm about joining Paige’s AppLab, emphasizing the importance of facilitating seamless integration of AI solutions to drive innovation in the field. Dr. Nasir Rajpoot, Co-Founder, and Chief Scientific Officer of Histofy, echoed this sentiment, highlighting the opportunity to make their groundbreaking AI solutions accessible to a growing community of pathologists and researchers through the Paige Platform.
Paige remains dedicated to delivering products designed for real-world clinical use, ensuring that each new application seamlessly integrates with existing Paige tools and applications. This cohesive approach creates a robust guidance engine that maximizes the potential of digital pathology and AI, ultimately enhancing the quality and efficiency of cancer diagnosis.
Jill Sue, Vice President of Product at Paige, expressed excitement about welcoming these six industry-leading digital pathology vendors to the Paige AppLab. She emphasized that their partnership underscores Paige’s commitment to innovation and cutting-edge technology, solidifying the AppLab as the go-to destination for all digital pathology needs.
Paige’s AppLab expansion marks a pivotal moment in the realm of cancer diagnosis. By welcoming top-tier digital pathology and AI providers, Paige empowers pathologists with unparalleled access to advanced diagnostic capabilities. This strategic move underscores Paige’s dedication to driving innovation and improving patient outcomes. As the landscape of digital pathology continues to evolve, Paige remains at the forefront, revolutionizing cancer diagnosis and shaping the future of healthcare.
